Marvel Biosciences Corp (MRVL) — Strategic Asset Allocation Index
Marvel Biosciences Corp (MRVL) has a Strategic Asset Allocation Index of 0.0% as of October 2021. Strategic assets (PP&E of CA$114.00 plus long-term investments of CA$-) total CA$114.00, measured against net assets of CA$1.85 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Marvel Biosciences Corp balance sheet quality to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Marvel Biosciences Corp Strategic Asset Allocation Index (2020–2021)
This chart shows how Marvel Biosciences Corp's Strategic Asset Allocation Index has evolved across 2 annual periods from 2020 to 2021. As of October 2021, the index stands at 0.0%, representing strategic assets of CA$114.00 against net assets of CA$1.85 Million CAD. For live market cap and overall valuation, see Marvel Biosciences Corp market capitalisation.
Annual Strategic Asset Allocation Index for Marvel Biosciences Corp (2020–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Marvel Biosciences Corp from 2020 to 2021, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See net assets of Marvel Biosciences Corp for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (CAD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 0.0% | CA$152.00 | CA$152.00 | CA$- | CA$2.36 Million | ▼ -0.3 pp |
| 2020 | 0.3% | CA$337.00 | CA$337.00 | CA$- | CA$118.80K | — |